Monthly Communication Report

Organization:	Innovative Medicines Canada/Médicaments novateurs Canada
Associated registration:	957857-371-128
Communication date:	2025-10-22
Posted date:	2025-11-12

Designated Public Office Holders who participated in the communication:	Rodrigo Arancibia, Acting Director General Life Sciences, Innovation, Science and Economic Development Canada (ISED)
List of Details Subject matter Detail Foreign Affairs, Health, Infrastructure, International Trade, Research and Development, Science and Technology, Small Business, Taxation and Finance Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry Health, Research and Development, Science and Technology, Taxation and Finance Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships Foreign Affairs, Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance Free trade agreements as they relate to the biopharmaceutical industry
Responsible Officer who filed this communication report:	Bettina Hamelin
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.